International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma

被引：25

作者：

van der Kwast, Theo ^{[1
]}

Liedberg, Fredrik ^{[2
,3
]}

Black, Peter C. ^{[4
]}

Kamat, Ashish ^{[5
]}

van Rhijn, Bas W. G. ^{[6
]}

Algaba, Ferran ^{[7
]}

Berman, David M. ^{[8
]}

Hartmann, Arndt ^{[9
]}

Lopez-Beltran, Antonio ^{[10
]}

Samaratunga, Hemamali ^{[11
]}

Varma, Murali ^{[12
]}

Cheng, Liang ^{[13
]}

机构：

[1] Princess Margaret Canc Ctr, Toronto, ON, Canada

[2] Lund Univ, Dept Translat Med, Malmo, Sweden

[3] Skane Univ Hosp, Dept Urol, Malmo, Sweden

[4] Univ British Columbia, Vancouver, BC, Canada

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands

[7] Univ Autonoma Barcelona, Fdn Puigvert, Barcelona, Spain

[8] Queens Univ, Kingston, ON, Canada

[9] Friedrich Alexander Univ Erlangen Nurnberg, Erlangen, Germany

[10] Cordoba Univ, Med Sch, Cordoba, Spain

[11] Univ Queensland, Aquesta Uropathol, Brisbane, Qld, Australia

[12] Univ Hosp Wales, Cardiff, Wales

[13] Indiana Univ, Sch Med, Indianapolis, IN 46204 USA

来源：

EUROPEAN UROLOGY FOCUS | 2022年 / 8卷 / 02期

关键词：

Bladder cancer; Grading system; WHO; 2004; 1973; Expert opinion; Non-muscle invasive bladder cancer; Pathology; INVASIVE BLADDER-CANCER; EUROPEAN ASSOCIATION; CLASSIFICATION; PROGRESSION; NEOPLASMS; HETEROGENEITY; BIOMARKERS; GUIDELINES; SUBTYPES; SYSTEMS;

D O I：

10.1016/j.euf.2021.03.017

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Context: Grading is the mainstay for treatment decisions for patients with non-muscle-invasive bladder cancer (NMIBC). Objective: To determine the requirements for an optimal grading system for NMIBC via expert opinion. Evidence acquisition: A multidisciplinary working group established by the International Society of Urological Pathology reviewed available clinical, histopathological, and molecular evidence for an optimal grading system for bladder cancer. Evidence synthesis: Bladder cancer grading is a continuum and five different grading systems based on historical grounds could be envisaged. Splitting of the World Health Organization (WHO) 2004 low-grade class for NMIBC lacks diagnostic reproducibility and molecular-genetic support, while showing little difference in progression rate. Subdividing the clinically heterogeneous WHO 2004 high-grade class for NMIBC into intermediate and high risk categories using the WHO 1973 grading is supported by both clinical and molecular-genetic findings. Grading criteria for the WHO 1973 scheme were detailed on the basis of literature findings and expert opinion. Conclusions: Splitting of the WHO 2004 high-grade category into WHO 1973 grade 2 and 3 subsets is recommended. Provision of more detailed histological criteria for the WHO 1973 grading might facilitate the general acceptance of a hybrid four-tiered grading system or-as a preferred option-a more reproducible three-tiered system distinguishing low-, intermediate (high)-, and high-grade NMIBC. Patient summary: Improvement of the current systems for grading bladder cancer may result in better informed treatment decisions for patients with bladder cancer. (C) 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.

引用

页码：438 / 446

页数：9

共 46 条

[1] The applicability and utility of immunohistochemical biomarkers in bladder pathology [J].